HLA-C and neoplasm: Major histocompatibility complex (MHC)-bound peptides that arise from tumor-specific neoantigen mutations, are promising targets for adoptive T-cell therapy with autologous tumor-infiltrating lymphocytes expressing endogenous TCRs, gene-modified T cells expressing novel T-cell receptors or chimeric antigen receptors (CAR) T cells comprising recombinant antibodies against extracellular cell surface molecules or TCR-like antibodies.